Savara Inc. $SVRA Stake Cut by Farallon Capital Management LLC

Farallon Capital Management LLC lessened its holdings in Savara Inc. (NASDAQ:SVRA) by 63.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,500,000 shares of the company’s stock after selling 4,335,000 shares during the quarter. Farallon Capital Management LLC owned approximately 1.23% of Savara worth $8,925,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Prudential Financial Inc. bought a new position in shares of Savara in the 2nd quarter worth about $30,000. BNP Paribas Financial Markets boosted its holdings in shares of Savara by 52.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock valued at $31,000 after buying an additional 4,626 shares during the period. Brevan Howard Capital Management LP bought a new stake in shares of Savara during the 2nd quarter valued at about $33,000. Russell Investments Group Ltd. grew its position in shares of Savara by 930.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock valued at $37,000 after buying an additional 9,463 shares during the last quarter. Finally, Quadrature Capital Ltd acquired a new stake in Savara during the second quarter worth about $42,000. Institutional investors own 87.93% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on SVRA. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a report on Thursday, January 22nd. UBS Group set a $10.00 target price on Savara in a report on Tuesday, December 23rd. Wells Fargo & Company increased their price target on Savara from $7.00 to $9.00 and gave the stock an “overweight” rating in a research report on Thursday, December 18th. Wall Street Zen downgraded Savara from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Guggenheim restated a “buy” rating on shares of Savara in a research report on Tuesday, December 23rd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.86.

Savara Stock Performance

Shares of SVRA opened at $5.25 on Monday. The firm has a market capitalization of $1.07 billion, a PE ratio of -9.91 and a beta of 0.31. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.32. The firm has a 50-day moving average price of $5.67 and a 200 day moving average price of $4.97. Savara Inc. has a 52-week low of $1.89 and a 52-week high of $7.01.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Friday, March 13th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). On average, sell-side analysts anticipate that Savara Inc. will post -0.45 earnings per share for the current fiscal year.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.